OCTOCELLS

Harnessing cellular bioproduction at scale can pave the way for a sustainable bioeconomy, and Octocells (formerly Fudzs) is at the forefront of this transformation. By combining advanced biomaterial engineering with cutting-edge cellular science and bioreactor technology, Octocells is revolutionizing the production of vaccines, cell therapies, regenerative medicine, and cultivated proteins. These industries face critical challenges in sustainability, efficiency, and cost-effectiveness, and Octocells’ innovative approach directly addresses these concerns.

Octocells is committed to revolutionizing bioproduction by developing cutting-edge, sustainable, and cost-effective cell manufacturing processes. The company's mission is threefold:

• Environmental Responsibility: Reducing the ecological footprint of traditional production methods through innovative biotechnological approaches.
• Public Health Advancement: Providing safe, bio-based solutions for cultivated food, regenerative medicine, and therapeutic applications.
• Industrial Sovereignty: Strengthening industry independence by making bio-based production more accessible and scalable.

By integrating expertise in biomaterial engineering, cellular science, and process automation, Octocells is shaping the future of a sustainable bioeconomy.

Octocells’ core innovation lies in its highly scalable and cost-effective bioproduction platform. This breakthrough enables the mass production of cells at unprecedented low costs, unlocking new commercial opportunities in industries such as cultivated meat, tissue engineering, and biopharmaceuticals.

Unlike conventional methods that struggle with efficiency and expense, Octocells leverages advanced bioreactor technology and process optimization. This approach allows for large-scale cell cultivation while maintaining high product quality, reducing resource consumption, and improving affordability.

Octocells seeks to make a positive societal impact across several UN Sustainable Development Goals:

• SDG 2: Zero Hunger
  Octocells contributes to global food security by making high-quality, cellularly produced foods affordable and accessible. Their high-density bioreactor technology maximizes yield while minimizing operational costs, enabling large-scale production at competitive prices.
• SDG 3: Good Health and Well-being
  Octocells provides safer, healthier products through controlled production environments. Smart process automation and AI-driven monitoring ensure consistency and reduce contamination risks, supporting public health with sustainable biosourced solutions.
• SDG 12: Responsible Consumption and Production
  The company reduces the environmental impact of production by cutting CO₂ emissions, water use, and land requirements. Localized facilities connected to nearby markets minimize waste and transportation, making sustainable and ethical production commercially viable.
• SDG 13: Climate Action
  Octocells' low-emission production methods actively contribute to reducing the carbon footprint of industrial processes and combating climate change.
• SDG 15: Life on Land
  By offering a sustainable alternative to intensive farming, Octocells helps protect biodiversity and prevent deforestation. The company also collaborates with farmers to promote environmentally respectful practices, supporting the development of a sustainable bioeconomy.

Octocells plans to leverage Dassault Systèmes' 3DEXPERIENCE platform to develop a digital twin of their bioreactor, enabling detailed simulation and optimization of both physical and biochemical production conditions. They also aim to create a virtual factory connected to the real facility to streamline operations, maintenance, training, and daily workflows, enhancing efficiency and scalability. Their next-generation bioproduction platform combines advanced bioreactor technology with high-density cell culture optimization, supporting large-scale, cost-effective, and sustainable cell production.

The founding team of Octocells brings together diverse expertise in biology, finance, and data science, fostering a multidisciplinary approach. They plan to expand the team by recruiting additional experts in biology and production and are actively engaging with companies and specialists in the sector. CEO and CSO Zied Souguir brings extensive experience in the biopharmaceutical industry, reinforcing strong connections to scientific research. Overall, the Octocells team combines over 50 years of collective expertise across chemistry, biology, artificial intelligence, and marketing, while also seeking strategic partnerships to support and accelerate their innovation.